View Older Stories View More Recent Stories

Mar 11, 2025 06:45AM Merck (MRK) Unveils New Facility to Increase Vaccine Production Capacity
Mar 11, 2025 06:45AM Merck Unveils New Facility to Increase Vaccine Production Capacity
Mar 9, 2025 01:21PM ROSEN, HIGHLY RECOGNIZED INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Mar 7, 2025 11:05PM ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Mar 6, 2025 07:57PM ROSEN, A TOP RANKED LAW FIRM, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Mar 5, 2025 07:52PM ROSEN, LEADING INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Mar 4, 2025 07:46PM TOP RANKED ROSEN LAW FIRM Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Mar 3, 2025 07:18PM ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Mar 2, 2025 07:02PM ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Mar 1, 2025 07:01PM ROSEN, A LEADING LAW FIRM, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Feb 28, 2025 06:56PM ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Feb 27, 2025 06:50PM ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Feb 26, 2025 05:28PM ROSEN, LEADING INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Feb 25, 2025 05:23PM ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Feb 25, 2025 06:45AM Merck (MRK) Granted FDA Priority Review to Application for KEYTRUDA Plus Standard of Care as Perioperative Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
Feb 25, 2025 06:45AM FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Standard of Care as Perioperative Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinom
Feb 24, 2025 02:23PM ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Feb 24, 2025 06:45AM Merck to Participate in the TD Cowen 45th Annual Health Care Conference
Feb 22, 2025 10:17PM ROSEN, A LEADING FIRM, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Feb 21, 2025 07:28PM ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Feb 19, 2025 03:44PM ROSEN, RECOGNIZED INVESTOR RIGHTS COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Feb 18, 2025 06:45AM Merck (MRK) Reports WELIREG Received First European Commission Approval for Two Indications
Feb 18, 2025 06:45AM WELIREG® (belzutifan) Receives First European Commission Approval for Two Indications
Feb 17, 2025 02:04PM ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Feb 15, 2025 09:25PM ROSEN, SKILLED INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Feb 14, 2025 02:30PM ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Feb 6, 2025 06:45AM Merck (MRK) Announces Phase 3 waveLINE-010 Trial Initiation Evaluating Zilovertamab Vedotin
Feb 6, 2025 06:45AM Merck Announces Phase 3 waveLINE-010 Trial Initiation Evaluating Zilovertamab Vedotin, an Investigational Antibody-Drug Conjugate, for the Treatment of Patients With Previously Untreated Diffuse Large
Feb 4, 2025 06:30AM Merck Announces Fourth-Quarter and Full-Year 2024 Financial Results
Jan 31, 2025 06:45AM Merck (MRK) Receives Positive EU CHMP Opinion for CAPVAXIVE
Jan 31, 2025 06:45AM Merck Receives Positive EU CHMP Opinion for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Adults
Jan 30, 2025 06:45AM Merck (MRK) to Stop Phase 3 HYPERION Trial Evaluating WINREVAIR Early and Move to Final Analysis
Jan 30, 2025 06:45AM Merck Announces Decision to Stop Phase 3 HYPERION Trial Evaluating WINREVAIR™ (sotatercept-csrk) Early and Move to Final Analysis
Jan 28, 2025 01:28PM Merck (MRK) Announces $10B Share Buyback
Jan 28, 2025 01:28PM Merck Announces Second-Quarter 2025 Dividend and $10 Billion Share Repurchase Authorization
Jan 27, 2025 06:45AM FDA Grants Priority Review to Merck’s Application for WELIREG® (belzutifan) for the Treatment of Patients With Advanced Pheochromocytoma and Paraganglioma (PPGL)
Jan 24, 2025 06:45AM Merck (MRK) and Eisai Provide Update on Phase 3 LEAP-015 Trial Evaluating KEYTRUDA Plus LENVIMA in Combination with Chemotherapy
Jan 24, 2025 06:45AM Merck and Eisai Provide Update on Phase 3 LEAP-015 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination with Chemotherapy in Patients with Certain Types of Gastroesop
Jan 23, 2025 08:00AM MilliporeSigma Partners with Opentrons Labworks, Inc., Supporting Lab of the Future
Jan 16, 2025 06:45AM Merck to Hold Fourth-Quarter and Full-Year 2024 Sales and Earnings Conference Call Feb. 4
Jan 8, 2025 06:48AM Merck's (MRK) GARDASIL Receives Expanded Approval for Males in China
Jan 8, 2025 06:48AM Merck’s GARDASIL® Receives Expanded Approval for Males in China
Jan 6, 2025 08:00AM MilliporeSigma Acquires HUB Organoids Holding B.V., Expands Next-Gen Biology Portfolio
Jan 6, 2025 06:45AM Merck to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Dec 20, 2024 06:45AM Merck (MRK) Closes Exclusive Global License Agreement for LM-299
Dec 20, 2024 06:45AM Merck Closes Exclusive Global License Agreement for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody
Dec 19, 2024 06:45AM Merck (MRK) Announces Topline Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir
Dec 19, 2024 06:45AM Merck Announces Topline Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) for the Treatment of Adults
Dec 18, 2024 06:45AM Merck (MRK) Enters into Exclusive Global License Agreement with Hansoh Pharma for Investigational Oral GLP-1 Receptor Agonist
Dec 18, 2024 06:45AM Merck Enters into Exclusive Global License Agreement with Hansoh Pharma for Investigational Oral GLP-1 Receptor Agonist
View More Recent Stories View Older Stories